Literature DB >> 24004397

Dysphagia could be the first presenting symptom of telbivudine-induced myopathy.

S W Lee, J H Jang, B J Kim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24004397     DOI： 10.1111/imj.12237

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


× No keyword cloud information.
  4 in total

1.  Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine.

Authors:  Li Chen; Cai Cheng; Bicui Chen; Yue Zhao; Jiming Zhang; Bin Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-11-14       Impact factor: 2.953

2.  Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination.

Authors:  Ya-Wen Yang; Meng-Kun Tsai; Ching-Yao Yang; Chih-Yuan Lee; Bor-Luen Chiang; Hong-Shiee Lai
Journal:  Clin Exp Nephrol       Date:  2020-03-26       Impact factor: 2.801

Review 3.  Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature.

Authors:  Jinxin Zheng; Minggui Deng; Xiaoliang Qiu; Zhong Chen; Duoyun Li; Xiangbin Deng; Qiwen Deng; Zhijian Yu
Journal:  J Med Case Rep       Date:  2017-11-27

4.  Clinicopathological Features of Telbivudine-Associated Myopathy.

Authors:  Tomica Ambang; Joo-San Tan; Sheila Ong; Kum-Thong Wong; Khean-Jin Goh
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.